Is Zoetis Inc (ZTS) undervalued? · P/E 25, rev $9.47B
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Zoetis Inc (ZTS) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ZTS revenue for 2025-12-31 was $9.47B. Net income was $2.67B. Revenue was up 2.3% from 2024-12-31 to 2025-12-31. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
ZTS currently screens at market cap $64.65B and trailing P/E 24.9. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ZTS 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ZTS to the stock page model before you treat a low multiple as a gift.
Not investment advice.